Reshma Shringarpure is Vice President of Clinical Research and Medical Affairs at Akero Therapeutics. She brings over 15 years of experience in clinical and medical affairs across multiple therapeutic areas including GI, non-viral liver disease, and metabolic disease. Reshma joins Akero from Intercept Pharmaceuticals, where she was the clinical lead for Intercept’s late-stage NASH program and was integral to achieving several company milestones, including breakthrough therapy designation for obeticholic acid (OCA) for the treatment of NASH, design and readout of the first positive Phase 3 clinical trial in NASH, and registrational filings in US and Europe. Prior to joining Intercept, she was the director of medical affairs responsible for medical affairs strategy and operations for a biologic to treat a rare disease at Santarus. Leading up to this role, Reshma held several scientific positions of increasing responsibility at Prometheus Therapeutics and Diagnostics as the clinical and medical affairs lead focused on Prometheus’ GI portfolio (IBS, IBD and celiac disease) and contributed to the clinical development of anti-TNF monitoring tests (ANSER® ADA, ANSER® IFX). She started her pharmaceutical career at Amylin Pharmaceuticals focusing on metabolic diseases and is a co-author of several peer-reviewed publications.
Reshma earned her PhD in molecular biology from the University of Southern California and completed her post-doctoral training at Dana Farber Cancer Institute, Harvard Medical School.